Spero Therapeutics, Inc. Research and Development Arrangement with Federal Government, Costs Incurred, Net
Spero Therapeutics, Inc. (SPRO) reported Research and Development Arrangement with Federal Government, Costs Incurred, Net of $6.90 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet · last filed 2025-03-27
- Spero Therapeutics, Inc. research and development arrangement with federal government, costs incurred, net for fiscal 2024 was $6.90M, a 2.82% decline from fiscal 2023.
- Spero Therapeutics, Inc. research and development arrangement with federal government, costs incurred, net for fiscal 2023 was $7.10M.
| Period end | Research and Development Arrangement with Federal Government, Costs Incurred, Net 12 month |
|---|---|
| 2024-12-31 | $6.90M 10-K · filed 2025-03-27 |
| 2023-12-31 | $7.10M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |